vorinostat
Phase 2Terminated 1 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Sickle Cell Disease
Conditions
Sickle Cell Disease, Sickle Cell Anemia
Trial Timeline
Oct 1, 2009 → Oct 1, 2014
NCT ID
NCT01000155About vorinostat
vorinostat is a phase 2 stage product being developed by Merck for Sickle Cell Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT01000155. Target conditions include Sickle Cell Disease, Sickle Cell Anemia.
What happened to similar drugs?
4 of 20 similar drugs in Sickle Cell Disease were approved
Approved (4) Terminated (9) Active (8)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (17)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01365065 | Phase 2 | UNKNOWN |
| NCT01319383 | Phase 1/2 | Completed |
| NCT00918489 | Phase 2 | Completed |
| NCT01000155 | Phase 2 | Terminated |
| NCT00821951 | Phase 1 | Completed |
| NCT00831493 | Phase 1/2 | Terminated |
| NCT00875056 | Phase 2 | Completed |
| NCT00735826 | Pre-clinical | Completed |
| NCT00838929 | Phase 1 | Completed |
| NCT00719875 | Phase 1 | Completed |
| NCT00771472 | Phase 1 | Completed |
| NCT00776503 | Phase 1/2 | Completed |
| NCT00561418 | Phase 1 | Completed |
| NCT00416130 | Phase 1/2 | UNKNOWN |
| NCT00907738 | Phase 2 | Completed |
| NCT00127127 | Phase 1 | Completed |
| NCT00127140 | Phase 1 | Completed |
Competing Products
20 competing products in Sickle Cell Disease